5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)

Therapeutic Areas

Nervous System DiseasesNeoplasmsImmune System Diseases+ [5]

Active Indication

Depressive Disorder, MajorDepressive Disorder, Treatment-ResistantBipolar II disorder+ [32]

Inactive Indication

AmnesiaBody Dysmorphic DisordersFragile X Syndrome+ [3]

Originator Organization-

Active Organization

Revive Therapeutics Ltd.

Filament Health Corp.

Mycomedica Life Sciences Pbc

+ [30]

Inactive Organization

The University of New Mexico

KGK Science, Inc.

Beckley Psytech Ltd.

+ [2]

License Organization

Revive Therapeutics Ltd.

Psyence Biomedical Ltd.

Psirenity

+ [16]

Drug Highest PhasePhase 3

First Approval Date-

RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Innovative Licensing and Access Pathway (United Kingdom)

Structure/Sequence

Molecular FormulaC12H17N2O4P

InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N

CAS Registry520-52-5

297

Clinical Trials associated with Psilocybin

NCT06005662

/ SuspendedPhase 2IIT

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

Start Date01 Apr 2027

Sponsor / Collaborator

The Johns Hopkins University

NCT07211438

/ Not yet recruitingPhase 2IIT

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression.

Start Date01 Apr 2026

Sponsor / Collaborator

Centre for Addiction & Mental Health

[+1]

ISRCTN14487299

/ RecruitingPhase 2

A Phase IIb multicentre, randomised, double-blind, two-arm trial comparing the efficacy and safety of 25 mg psilocybin plus psychological support versus 5 mg psilocybin plus psychological support in adults with severe generalized anxiety disorder (GAD) (PSiGAD2)

Start Date01 Apr 2026

Sponsor / Collaborator

Incannex Healthcare, Inc.

100 Clinical Results associated with Psilocybin

100 Translational Medicine associated with Psilocybin

100 Patents (Medical) associated with Psilocybin

2,489

Literatures (Medical) associated with Psilocybin

01 Jan 2026·JOURNAL OF AFFECTIVE DISORDERS

Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal

Review

Author: Rosenblat, Joshua D ; Hawco, Colin ; Sabbah, Sami George ; Li, Sophie ; McIntyre, Roger S ; Badulescu, Sebastian ; Wong, Sabrina ; Le, Gia Han

BACKGROUND:

Psychedelics are emerging as promising treatments for major depressive disorder (MDD) and treatment-resistant depression (TRD). Functional magnetic resonance imaging (fMRI) offers a powerful tool to study neural mechanisms underlying therapeutic response.

METHODS:

This systematic review (PROSPERO #CRD42024557973) examined neuroimaging studies of psilocybin in MDD and TRD, with a focus on the temporal evolution of neuroimaging changes post-treatment. A secondary aim was to correlate imaging findings with validated clinical outcomes to assess their relevance in predicting treatment response.

RESULTS:

Eleven eligible studies were included, using diverse fMRI modalities such as resting-state functional connectivity, task-based BOLD imaging, amplitude of low-frequency fluctuations (ALFF), dynamic functional connectivity, and magnetic resonance spectroscopy. Early (0-4 weeks) post-treatment changes included reduced network modularity and increased global brain integration, alongside modulation of affective circuits involving the amygdala, default mode network, and prefrontal regions. These changes were significantly associated with reductions in BDI, QIDS, and SHAPS scores, reflecting improvements in mood and anhedonia. Longer-term changes (5+ weeks) involved sustained reorganization of large-scale networks, particularly increased connectivity between the prefrontal and parietal cortices and salience network.

CONCLUSIONS:

Although these findings suggest psilocybin is associated with dynamic and temporally distinct neuroplastic changes linked to clinical improvement, several limitations must be acknowledged. Many studies reused overlapping datasets with high exploratory flexibility and risk of bias. The generalizability of results is therefore constrained. Future research should emphasize independent datasets, pre-registered imaging endpoints, and longitudinal designs to clarify the mechanisms underlying psychedelic therapy for depression.

01 Dec 2025·Current Pain and Headache Reports

Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management

Review

Author: Strand, Natalie H ; Gomez, Diego ; Leathem, James ; Viswanath, Omar ; Whitney, Madeline ; Johnson, Brooks ; Attanti, Sumedha ; Maloney, Jillian ; Misra, Lopa ; Dunn, Tyler ; Emami, Eric

PURPOSE OF REVIEW:

Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.

RECENT FINDINGS:

These substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.

01 Dec 2025·Current Pain and Headache Reports

Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights

Review

Author: Henderson, Isabella ; Duarte, Robert A ; Vadhan, Nehal P ; Chan, Gabriel ; Elsaadany, Ronnie ; Goodman, Sadie ; Grunstein, Michael ; Duarte, Diana ; Bajaj, Vikram

PURPOSE OF REVIEW:

Exploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed.

RECENT FINDINGS:

Psychedelics demonstrate promising outcomes as treatments for headache disorders. Recent findings indicated that some patients who underwent brief periods of treatment with psychedelics experienced a reduction in headache attack frequency, severity, or duration. When prescription medications are ineffective at treating headache disorders, or are habit-forming, patients often turn to alternative options. There is anecdotal evidence that psychedelic drugs like LSD and psilocybin can effectively treat and prevent pain in patients with headache disorders, such as migraine or cluster headache. It is vital that physicians treating patients who self-treat with psychedelics be well-informed about the mechanisms and their effects to best advise their patients and coordinate their care well. This is a review assessing the literature on the mechanisms, safety, and efficacy of psychedelic drugs as a headache management intervention. We believe there is evidence that may support further investigation into the clinical use of psychedelic medications to treat cluster headache and migraine, including the consideration of use in conjunction with other interventions like cognitive behavioral therapy or acceptance and commitment training.

1,038

News (Medical) associated with Psilocybin

02 Oct 2025

·www.prnewswire.com

Psilera Inc. Secures National Institutes of Health Grant for AUD Research

Small Business Innovation Research Grant will advance a novel neuroplastogen towards IND as potential treatment for Alcohol Use Disorder (AUD). The 3-year, milestone-driven grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) is worth up to $2 million. TAMPA, Fla., Oct. 2, 2025 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biotechnology company developing groundbreaking therapies for hard-to-treat neurological and mental health disorders, today announced receipt of a grant from the National Institutes of Health (NIH) to conduct research on AUD. The governmental endorsement of Psilera's research bolsters the company's vision of providing first-in-class treatment options for underserved patient populations. Continue Reading "We are thankful to the NIH for this funding which will enable us to quickly advance our research into AUD," said Dr. Jackie von Salm, Co-founder and CSO of Psilera. "Neuroplastogens hold tremendous promise in treating a range of devastating and debilitating diseases, and this endorsement further emphasizes their potential as a future addiction therapy." Psilera receives $2 million NIH grant for AUD. Post this In the U.S., nearly 30 million adults are affected by AUD with only around 8% of patients seeking treatment. Psilera recognizes the huge unmet need across this population, and believes neuroplastogens - compounds that help reshape neuronal pathways in the brain - could aid patients in breaking out of entrenched thought and behavior patterns. In pre-clinical studies, Psilera's novel psilocybin derivative shows potential as a new, non-opioid treatment for alcohol consumption. Leveraging the Psilera Third Eye™ platform, this unique neuroplastogen was selected from a large compound library and screening campaign focused on the serotonin receptor 5-HT2A. It has passed initial pre-clinical safety and toxicity assessments and specifically targets the serotonergic and glutaminergic pathways often affected by AUD. This new therapy from Psilera, if approved, would provide AUD patients with a non-hallucinogenic and non-addictive treatment alternative where there currently isn't one. Ideally, this could allow for at-home administration of therapy, greatly reducing the stigma and burdens around AUD treatment. About Psilera: Psilera is a biotechnology research and development company founded to create medicines that change the way the world thinks. By harnessing the potential of natural products, the company advances neuroplastic therapies to help patients suffering from neurodegeneration and addiction. Psilera has amassed a leading pipeline of next-generation neuroplastogens including PSIL-006, a first-in-class therapeutic for the treatment of frontotemporal dementia (FTD). To learn more about this new era in mindful medicine visit . Media Contact: Psilera Inc. Michael Lauer MDL Strategic Communications [email protected] SOURCE Psilera Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

30 Sep 2025

·www.globenewswire.com

Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses

-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 Trial of RE104 in Postpartum Depression (PPD) in 2026 and RECLAIM Phase 2 Trial in Generalized Anxiety Disorder (GAD) in 1Q 2026-- MORRISTOWN, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced the dosing of the first patient in REKINDLE, a Phase 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other medical illnesses. Topline results from the study are anticipated in 2027. With RE104, Reunion Neuroscience aims to offer patients an effective, safe and fast-acting psychotropic medication to relieve distress and dysfunction in patients with AjD. RE104 is the only psychedelic therapeutic in advanced clinical development for an AjD indication in the United States. “AjD is an area of significant need for patients with cancer and other serious diseases, both because of the depressive and anxiety symptoms it introduces and the poorer medical outcomes it can engender,” said Manish Agrawal, M.D., Co-Founder and Chief Executive Officer of Sunstone Therapies and REKINDLE investigator. “The unique mechanism of action of RE104, designed to deliver both rapid and sustained benefit, represents a promising new approach that may transform the treatment of patients suffering from AjD. I am proud to be part of this pioneering effort and look forward to evaluating RE104 in REKINDLE.” “Dosing the first patient in our REKINDLE Phase 2 trial marks a significant milestone in our mission to bring RE104 to patients living with underserved mental health disorders. AjD is a debilitating and underrecognized condition that affects the emotional well-being and medical outcomes of approximately 500,000 people in the United States each year, and for which there are currently no approved options,” said Greg Mayes, President and Chief Executive Officer of Reunion Neuroscience. “Our confidence in RE104 is buoyed by positive topline data from the RECONNECT trial of RE104 for the treatment of PPD, which demonstrated RE104’s ability to deliver rapid and safe symptom relief following a single dose. We look forward to bringing similar benefit to patients facing the emotional toll of cancer and other serious medical illnesses, as we expand our clinical development efforts and work to realize the full potential of RE104.” The REKINDLE Phase 2 clinical trial (NCT07002034) is a randomized, double-blind, parallel-group, dose-controlled clinical trial evaluating the safety and efficacy of RE104 for the treatment of AjD in adult patients with cancer and other medical illnesses. The primary endpoint of the trial is the change from baseline in total Montgomery-Åsberg Depression Rating Scale (MADRS) score, a clinician rated scale measuring depression severity. A key secondary endpoint of the trial is the change from baseline in the Hamilton Anxiety Scale (HAM-A), a clinician rated scale measuring anxiety severity. The study will also assess the safety and tolerability of RE104. Reunion Neuroscience recently announced topline data from RECONNECT (NCT06342310), a multicenter, randomized, double-blind, dose-controlled Phase 2 clinical trial evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. RECONNECT met its primary endpoint, demonstrating a clinically-meaningful reduction in MADRS scores through Day 28, as well as a favorable safety and tolerability profile. These data support Reunion Neuroscience’s plans to advance RE104 into a Phase 3 trial for the treatment of PPD in 2026. Reunion Neuroscience also plans to commence RECLAIM, a Phase 2 clinical trial in Generalized Anxiety Disorder (GAD), in the first quarter of 2026. About Adjustment Disorder (AjD)AjD is a mental health condition defined as a disproportionate reaction to a stressful life event or change, which impacts the ability to function and is characterized by depression, anxiety and/or other behavioral and mood disturbances. Serious medical illnesses are known to be a key precipitant of AjD; it is estimated that approximately 500,000 people in the United States are diagnosed with AjD each year following a medical or health-related stressor. Depressive and anxiety symptoms in medically ill patients with AjD can be associated with poorer medical outcomes, treatment compliance and quality of life as well as increased health care utilization. Current treatments for AjD are not consistently effective, and there are no therapies presently approved by the U.S. Food and Drug Administration (FDA) for its treatment. Additional information on RE104’s potential in AjD can be found in the white paper authored by Reunion Neuroscience, “Adjustment Disorder Associated With Medical Illness: Unmet Needs and Rationale for RE104 as a Novel Psychedelic Therapy.” About RE104The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, which is administered via a single subcutaneous injection. Reunion designed RE104 to deliver a shorter acute psychoactive experience when compared to longer experience duration psychedelics such as psilocybin or LSD. About Reunion Neuroscience, Inc.Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression, adjustment disorder and generalized anxiety disorder and may in the future expand to additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care. Reunion has advanced a lead candidate, RE245, from its non-psychedelic discovery program and plans to file an IND in 2026. To learn more, visit https://reunionneuro.com, and follow Reunion on LinkedIn and Bluesky. For further information:IR Inquiries:Hannah DeresiewiczPrecision AQhannah.deresiewicz@precisionaq.com PR Inquiries:Ashley Murphy Precision AQashley.murphy@precisonaq.com

Phase 2

26 Sep 2025

·www.globenewswire.com

PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand

Sept. 25, 2025 -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has signed a distribution agreement with Veridion Group (“Veridion”) of New Zealand, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market. “With the approval of the first Authorized Prescriber for Psilocybin by Medsafe – the New Zealand Medicines and Medical Devices Safety Authority – we immediately saw a number of eminent clinicians express a desire to do the same for MDMA,” said Nick Kadysh, CEO, PharmAla Biotech. “We’re incredibly pleased to have partnered with Veridion to act as our exclusive distributor for New Zealand. Veridion has the expertise we look for in a partner: executing complex operations with controlled pharmaceuticals, and working with doctors to provide exceptional care. Kia ora!” The distribution agreement includes an annual purchase minimum (waived for the first year), as well as restrictions on re-export. PharmAla anticipates shipping to New Zealand from existing inventory allocated for its Australian operations. “This partnership with PharmAla is a natural fit. Veridion has built its reputation on handling complex, highly regulated medicines, and PharmAla brings both the science and the track record to match,” said Courtney Letica, CEO, Veridion Group. “Together, we can give New Zealand clinicians confidence that when MDMA treatments become available, access will be safe, controlled, and delivered to the highest standard.” PharmAla is furthermore pleased to appoint Dr. Kiyan Afzali to the board of PharmAla Biotech Australia Pty Ltd. (“PharmAla Australia”). Dr. Afzali is a scientific consultant with nearly a decade of experience in leading impactful translational research through broad expertise in medicine, pharmacology, and drug discovery, and a specialisation in quantitative pharmacodynamics. He earned his PhD from The University of Sydney, where he developed small drug-like molecules as the first potential medicines targeting the receptor for oxytocin, also known as the love hormone or social neuropeptide, to treat some of the largest contributors to the global burden of disease, including neuropsychiatric disorders, cardiometabolic disease, pain, and inflammation. His works have led and instrumentally contributed to significant written compositions, licensed patents, awards, a total of $282m in private investment, and the establishment and maturation of the biotechnology company Kinoxis Therapeutics, including a strategic partnership with the major international pharmaceutical company Boehringer Ingelheim. “We’re pleased to welcome Dr. Afzali to the team, and look forward to consulting with him on our research and development efforts in Australia, “said Dr. Harpreet Kaur, VP of Research, PharmAla Biotech. “We believe his exceptional expertise in our field of study – as well as his proven track record of commercial success – will help us continue developing PharmAla into the best drug developer of MDMA-like molecules in the world.” Dr. Afzali’s appointment is effective October 1, 2025. PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. The content above comes from the network. if any infringement, please contact us to modify.

Executive ChangeLicense out/in

100 Deals associated with Psilocybin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Psilocybin	-	DB11664

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Major	Phase 3	United States	Usona Institute	13 Mar 2024
Depressive Disorder, Treatment-Resistant	Phase 3	United States	Compass Pathways Plc	19 Jan 2023
Stimulant abuse	Phase 2	-	Filament Health Corp.	01 Jan 2025
Opioid abuse	Phase 2	-	Filament Health Corp.	01 Dec 2024
Irritable Bowel Syndrome	Phase 2	United States	Tryp Therapeutics, Inc.	17 Jan 2024
Borderline Personality Disorder	Phase 2	United States	Usona Institute	01 Nov 2023
Neoplasms	Phase 2	United States	Sunstone Medical LLC	23 Oct 2023
Fibromyalgia	Phase 2	United States	University of Michigan	27 Sep 2023
Generalized anxiety disorder	Phase 2	Canada	Diamond Therapeutics, Inc.	24 Jan 2023
Mild depression	Phase 2	Canada	-	01 Jan 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04950608 (PATH, CTgov)	Phase 2	Disease Progression \| Advanced cancer	15	Psilocybin	fhdkaocpnj = yfiemhmipo xwdwdpfwgn (uauzwnczxl, vdylzbrxkl - dgauonngkk) View more	-	02 Sep 2025
NCT04424225 (CTgov)	Phase 1	Psychedelic \| Perceptual Disorders \| Visual Suppression	10	Psilocybin (Psilocybin)	vzysalxsrv(viwzwrjtuk) = ofqiuysqjo sfkqugjanq (qbbjxqwdyd, .11731) View more	-	27 Jun 2025
NCT04424225 (CTgov)	Phase 1	Psychedelic \| Perceptual Disorders \| Visual Suppression	10	Niacin (Niacin)	vzysalxsrv(viwzwrjtuk) = varecavkrw sfkqugjanq (qbbjxqwdyd, .04398) View more	-	27 Jun 2025
NCT05312151 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	22	Psilocybin	doiuuixzwi = szbkycvfsv dubiqsrjmt (jxhxhxdofg, yubmkeoshn - pvsikfxtqi) View more	-	13 Jun 2025
NCT05847686 (CTgov)	Phase 1/2	Neoplasm Metastasis \| Metastatic Solid Tumor \| Hematologic Neoplasms ... View more	55	Counseling+Psilocybin	pbpmccnbvc = wmbbwfjmhj mrnfsiucma (fkdxnrcbqe, kxvsiiqpmm - zzgkygzguu) View more	-	30 Apr 2025
NCT05128162 (CTgov)	Phase 2	Fibromyalgia	17	Psilocybin	yukyhxpxer(yhqzjrggmo) = lwqhyjjxui aqjjcesbqn (kdoydrtahb, joxzvreqvl - wdclcqdpij) View more	-	16 Apr 2025
NCT04141501 (Pubmed \| EClinicalMedicine)	Phase 2	Alcohol Use Disorder	37	Psilocybin (25 mg)	jllpaiukbr(fzufoggxju) = hgzyxjikvw gsptqpnjjr (ikbnxlgyrk, 14.31 - 19.29) View more	Negative	01 Apr 2025
NCT04141501 (Pubmed \| EClinicalMedicine)	Phase 2	Alcohol Use Disorder	37	Placebo (mannitol)	jllpaiukbr(fzufoggxju) = lwtrhfhsau gsptqpnjjr (ikbnxlgyrk, 10.97 - 16.63) View more	Negative	01 Apr 2025
NCT05163496 (CTgov)	Phase 3	Post Acute COVID 19 Syndrome \| Burnout, Professional \| Stress Disorders, Post-Traumatic	30	Psilocybin (Psilocybin Arm)	wvbbxtkiak(ghgtkirrbm) = hwflzwalci jgglgypatp (rqmeuaqnbb, 7.84) View more	-	18 Mar 2025
NCT05163496 (CTgov)	Phase 3		30	Active placebo (Placebo)	wvbbxtkiak(ghgtkirrbm) = iaiqscpkzd jgglgypatp (rqmeuaqnbb, 7.32) View more	-	18 Mar 2025
NCT04718792 (Company_Website \| Pubmed) Manual	Phase 2	Alcohol Use Disorder	10	PEX010	kdkijjoliw(blbavmblzs) = mshdjqvfbd dcvxcuzgem (nzescvwvjn, −61.1 - −13.9) View more	Positive	17 Mar 2025
NCT04433858 (Pubmed \| J Affect Disord)	Phase 2	Depressive Disorder, Treatment-Resistant	15	Psilocybin 25 mg	lwfywcekhu(manywxhdha) = narxscdtmk hmwjghzcup (nywmdxrvyy ) View more	Positive	01 Jan 2025
NCT03429075 (Psilodep-RCT, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Placebo (Psilocybin)	ahbybmhnua(inroulrstn) = fhwkpbbami zhvzfoptgz (jbrdfnggtm, 0.45) View more	-	24 Oct 2024
NCT03429075 (Psilodep-RCT, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Escitalopram (Escitalopram)	ahbybmhnua(inroulrstn) = nhvbifmjyh zhvzfoptgz (jbrdfnggtm, 0.62) View more	-	24 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis